OrbusNeich announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) Post Market Registry) to evaluate the Combo stent for the treatment of coronary lesions in the setting of routine clinical care.

Researchers have announced the results of a study that used speckle-tracking echocardiography (STE) to analyze early phase one results from the multi-center COMPASSION trial, which seeks to examine the safety and efficacy of a new option to replace dysfunctional pulmonary valves in a subset of congenital heart disease patients.

June 23, 2014 — Edwards Lifesciences Corp. announced that three-year clinical outcomes of its Edwards Intuity valve platform demonstrated improved cardiac and valvular performance, as well as patient functional status.

June 23, 2014 — Researchers have announced the results of a study that used contrast ultrasound molecular imaging (CMI) to examine a relatively new role for platelets at early to mid stages of atherosclerosis. Atherosclerosis, or hardening of the arteries due to plaque buildup, can lead to many serious health problems, including stroke and coronary heart disease.

Less aggressive anticoagulation therapy, combined with low-dose aspirin, can be used safely in conjunction with a newer generation mechanical heart valve. These findings from the first phase of a randomized clinical trial are published in The Journal of Thoracic and Cardiovascular Surgery, an official publication of the American Association for Thoracic Surgery.